Results 171 to 180 of about 355,709 (346)

Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial

, 2000
P. Kosmidis, N. Mylonakis, Dimosthenis Skarlos, E. Samantas, Meletios Α. Dimopoulos, C. Papadimitriou, C. Kalophonos, Nicholas Pavlidis, Christos Nikolaidis, Ch. Papaconstantinou, George Fountzilas   +10 more
openalex   +1 more source

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

Cancer Communications, EarlyView.
Abstract Background Glecirasib, an inhibitor of Kirsten rat sarcoma viral oncogene homolog glycine‐to‐cysteine substitution at codon 12 (KRAS G12C), has exhibited clinical activity in non‐small‐cell lung cancer (NSCLC) and colorectal cancer (CRC).
Jian Li, Ting Deng, Yanhong Gu, Antonio Calles Blanco, Zhihua Li, Chunmei Bai, Lin Wu, Jing Huang, Xingya Li, Yu Yao, Zhengbo Song, Yongsheng Li, Lian Liu, Ligang Xing, Wenming Wu, Julia Martínez‐Pérez, Ayala Hubert, Jon Zugazagoitia, Jian Zhang, Yongsheng Wang, Yanqiu Zhao, Guilan Wen, Guohao Xia, Diansheng Zhong, Xueqin Chen, Kuirong Jiang, Andrea Wang‐Gillam, Yuli Ding, Sumei Liu, Zhiyue Rao, Xinghu Liu, Lin Shen   +31 more
wiley   +1 more source

Vinorelbine—gemcitabine in advanced non-small-cell lung cancer (NSCLC): An AASLC phase II trial

, 2000
G. Krajnik, Andrea Mohn-Staudner, J. Thaler, Richard Greil, Susanne Schmeikal, Franz Marhold, Julia Deutsch, Pavel Preiss, R. Malayeri, C. Schäfer-Prokop, Wolfgang Wein, H. Huber, Robert Pirker   +12 more
openalex   +1 more source

Mechanism and role of regulated cell death in tumor immunity and immunotherapy

Cancer Communications, EarlyView.
Abstract Cancer immune checkpoint inhibitors (ICIs) have brought breakthroughs, but only about one‐third of cancer patients benefit from ICIs. In recent years, targeting non‐apoptotic regulated cell death (RCD) subtypes, such as ferroptosis, necroptosis, autophagy, cuproptosis, and pyroptosis, has emerged as a novel strategy in cancer therapy due to ...
Jingwen Hu, Yan Li, Bingjie Lian, Yitao Mao, Luqing Zhao   +4 more
wiley   +1 more source

CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer

Cancer Communications, EarlyView.
Abstract Background Third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show initial efficacy in EGFR‐mutated lung cancer, but residual disease persists. This study aimed to investigate cluster of differentiation 24 (CD24) as a translational immunotherapeutic target for enhancing third‐generation EGFR‐TKI efficacy.
Jiaqi Liang, Guoshu Bi, Xiaolong Huang, Zhijie Xu, Yiwei Huang, Yunyi Bian, Guangyao Shan, Wei Guo, Yuanliang Yan, Qihai Sui, Xiaodong Yang, Zhencong Chen, Tao Lu, Huan Zhang, Qun Wang, Wei Jiang, Cheng Zhan   +16 more
wiley   +1 more source

Thorascopic wedge resection and radiotherapy for T1N0 non-small cell lung cancer (NSCLC) in high risk patients: Preliminary analysis of a cancer and leukemia group B and Eastern Cooperative Oncology Group phase II trial

, 2000
H Shennib, Jeffrey A. Bogart, James E. Herndon, Leslie J. Kohman, D J Sugarbaker, Robert J. Keenan, T. Fitzgerald, A. Turrisi, M.R Green   +8 more
openalex   +1 more source

Green‐Synthesised Nanoconjugates: Advancing Targeted Photodynamic Therapy for Lung Cancer

Chemistry &Biodiversity, EarlyView.
ABSTRACT Lung cancer is a type of cancer that develops around the airways or lungs and continues to be the leading cause of cancer‐related deaths worldwide. This has necessitated the need for innovative therapeutic strategies to overcome the limits of existing therapies such as surgery, chemotherapy and radiotherapy.
Njabulo Henry Sibanda, Anine Crous, Blassan P. George   +2 more
wiley   +1 more source

Biological target volume (BTV) determined with dose response data from the correlation between metabolic rate of glucose (MRG) measured with 18F-FDG PET and pathologic complete response (PCR) in stage III non-small cell lung cancer (NSCLC)

, 2000
Noah C. Choi, A. Fischman, Sabrina García de Aquino, Andrzej Niemierko, Marek Ancukiewicz   +4 more
openalex   +1 more source

Molecular Docking and Target‐Specific Binding Profiles of Benzosuberane‐Based Compounds

ChemMedChem, EarlyView.
Benzosuberane represents a promising scaffold in medicinal chemistry. Several benzosuberane‐based derivatives are described in this review as anticancer agents, including antivascular agents, DNA‐intercalators, receptor modulators and kinase inhibitors.
Michail A. Saragatsis, Gemma K. Kinsella, James F. Curtin, Tao Zhang   +3 more
wiley   +1 more source

Plasma PGE-2 levels and altered cytokine profiles in adherent peripheral blood mononuclear cells in non-small cell lung cancer (NSCLC). [PDF]

, 2002
Giovanna E. Hidalgo, Zhong Li, Dennis E. Doherty, Edward A. Hirschowitz   +3 more
openalex   +1 more source